Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Diabetes mellitus4971 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A49192 | 14585066 | Expert Opin Drug Saf | Hepatotoxicity of thiazolidinediones. | 2003 | Details |
| A49204 | 35829988 | J Endocrinol Invest | Chinese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease have lower serum osteocalcin levels compared to individuals with type 2 diabetes mellitus and no liver disease: a single-center cross-sectional study. | 2022 | Details |
| A49208 | 35822119 | JGH Open | Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study. | 2022 | Details |
| A49210 | 35821558 | Curr Diab Rep | Lipodystrophy for the Diabetologist-What to Look For. | 2022 | Details |
| A49212 | 35818084 | Eur J Med Res | Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes. | 2022 | Details |
| A49219 | 35818404 | J Hepatocell Carcinoma | Understanding the Role of Metabolic Syndrome as a Risk Factor for Hepatocellular Carcinoma. | 2022 | Details |
| A49220 | 35818251 | Cell Mol Biol (Noisy-le-grand) | Effects of endoplasmic reticulum stress, liver function, insulin resistance and vascular endothelial function in patients with nonalcoholic fatty liver disease. | 2022 | Details |
| A49223 | 35817047 | Exp Clin Endocrinol Diabetes | Comorbidities in Mild Autonomous Cortisol Secretion - A Clinical Review of Literature. | 2022 | Details |
| A49224 | 35816948 | Diabetes Metab Syndr | Carotid intima media as predictor of liver fibrosis in type 2 diabetes mellitus with NAFLD. | 2022 | Details |
| A49228 | 35814521 | J Clin Exp Hepatol | Quantitative Ultrasound Assessment of Hepatic Steatosis. | 2022 | Details |
| A49235 | 35812989 | EClinicalMedicine | Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis. | 2022 | Details |
| A49246 | 35811319 | BMC Gastroenterol | Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey. | 2022 | Details |
| A49269 | 35806284 | Int J Mol Sci | Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A49271 | 35806010 | Int J Mol Sci | MAFLD and CKD: An Updated Narrative Review. | 2022 | Details |
| A49298 | 35795637 | Front Med (Lausanne) | A Novel Non-Invasive Approach Based on Serum Ceruloplasmin for Identifying Non-Alcoholic Steatohepatitis Patients in the Non-Diabetic Population. | 2022 | Details |
| A49331 | 35786482 | Sheng Wu Gong Cheng Xue Bao | [Lipid characteristics of fatty liver induced by high expression of Golgi protein 73]. | 2022 | Details |
| A49336 | 35784568 | Front Endocrinol (Lausanne) | Multi-Faceted Influence of Obesity on Type 1 Diabetes in Children - From Disease Pathogenesis to Complications. | 2022 | Details |
| A49339 | 35784296 | Front Immunol | Liver Fibrosis in Primary Sjögren's Syndrome. | 2022 | Details |
| A49340 | 35783879 | Cureus | Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. | 2022 | Details |
| A49361 | 35778734 | Cardiovasc Diabetol | TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients. | 2022 | Details |
| A49395 | 35765060 | Cell Biosci | Novel insights into non-alcoholic fatty liver disease and dementia: insulin resistance, hyperammonemia, gut dysbiosis, vascular impairment, and inflammation. | 2022 | Details |
| A49399 | 35764198 | J Ethnopharmacol | Exploring therapeutic mechanisms of San-Huang-Tang in nonalcoholic fatty liver disease through network pharmacology and experimental validation. | 2022 | Details |
| A49404 | 35761888 | Diabetes Metab Syndr Obes | Risk Factors for Nonalcoholic Fatty Liver Disease in Postmenopausal Women with Type 2 Diabetes Mellitus and the Correlation with Bone Mineral Density at Different Locations. | 2022 | Details |
| A49406 | 35760549 | BMJ Open | Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study. | 2022 | Details |
| A49418 | 35757255 | Front Nutr | Curcuminoids for Metabolic Syndrome: Meta-Analysis Evidences Toward Personalized Prevention and Treatment Management. | 2022 | Details |
| A49447 | 35747175 | EClinicalMedicine | The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy. | 2022 | Details |
| A49458 | 35745091 | Nutrients | Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang. | 2022 | Details |
| A49459 | 35744831 | Molecules | Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends. | 2022 | Details |
| A49460 | 35744822 | Molecules | Neuroendocrine-Immune Regulatory Network of Eucommia ulmoides Oliver. | 2022 | Details |
| A49469 | 35743358 | J Clin Med | When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD. | 2022 | Details |
| A49486 | 35740032 | Antioxidants (Basel) | NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook. | 2022 | Details |
| A49493 | 35738176 | Biomed Pharmacother | Sex hormone binding globulin as a potential drug candidate for liver-related metabolic disorders treatment. | 2022 | Details |
| A49513 | 35729970 | Curr Treat Options Gastroenterol | Liver Diseases in Latin America: Current Status, Unmet Needs, and Opportunities for Improvement. | 2022 | Details |
| A49516 | 35728961 | Cas Lek Cesk | Diagnosis of non-alcoholic fatty liver disease and its active screening in risk groups. | 2022 | Details |
| A49517 | 35728960 | Cas Lek Cesk | Metabolic dysfunction-associated fatty liver disease (MAFLD) as a more accurate name for NAFLD - common aspects of pathogenesis. | 2022 | Details |
| A49529 | 35725419 | BMC Pregnancy Childbirth | The association between chronic liver diseases and preeclampsia. | 2022 | Details |
| A49530 | 35724509 | Biomed Pharmacother | Diet-gut microbiota-epigenetics in metabolic diseases: From mechanisms to therapeutics. | 2022 | Details |
| A49547 | 35719604 | Front Public Health | Australian State and Territory Eclectic Approaches to Obesity Prevention in the Early Years: Policy Mapping and Perspectives of Senior Health Officials. | 2022 | Details |
| A49548 | 35718339 | Mol Metab | Hepatocyte cholesterol content modulates glucagon receptor signalling. | 2022 | Details |
| A49551 | 35717907 | Biochem Biophys Res Commun | S100A9 promotes inflammatory response in diabetic nonalcoholic fatty liver disease. | 2022 | Details |
| A49558 | 35714570 | Biochem Biophys Res Commun | TSC22D4 promotes TGFβ1-induced activation of hepatic stellate cells. | 2022 | Details |
| A49560 | 35713854 | Obes Surg | Endoscopic Bariatric Treatment with Duodenal-Jejunal Bypass Liner Improves Non-invasive Markers of Non-alcoholic Steatohepatitis. | 2022 | Details |
| A49565 | 35712241 | Front Endocrinol (Lausanne) | Circulating Ism1 Reduces the Risk of Type 2 Diabetes but not Diabetes-Associated NAFLD. | 2022 | Details |
| A49572 | 35709779 | Acta Gastroenterol Belg | Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ? | 2022 | Details |
| A49574 | 35709586 | Diabetes Metab Syndr | Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis. | 2022 | Details |
| A49575 | 35709466 | PLoS One | Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-Registry. | 2022 | Details |
| A49577 | 35708630 | J Med Food | Nil-Surin Rice Bran Hydrolysates Improve Lipid Metabolism and Hepatic Steatosis by Regulating Secretion of Adipokines and Expression of Lipid-Metabolism Genes. | 2022 | Details |
| A49587 | 35702836 | J Assoc Physicians India | Interrelation of the Risk Factors of NAFLD at various Stages of Progression of the glycemic Status on long-term Follow-up. | 2022 | Details |
| A49588 | 35702577 | Intractable Rare Dis Res | Diagnosing Alström syndrome in a patient followed up with syndromic obesity for years. | 2022 | Details |
| A49589 | 35701716 | Hepatol Int | A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population. | 2022 | Details |
| A49609 | 35692676 | J Clin Biochem Nutr | Pre-germinated brown rice alleviates non-alcoholic fatty liver disease induced by high fructose and high fat intake in rat. | 2022 | Details |
| A49611 | 35692404 | Front Endocrinol (Lausanne) | Non-Alcoholic Fatty Liver Disease (NAFLD) Is an Independent Risk Factor for Developing New-Onset Diabetes After Acute Pancreatitis: A Multicenter Retrospective Cohort Study in Chinese Population. | 2022 | Details |
| A49612 | 35692179 | Obes Rev | Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. | 2022 | Details |
| A49623 | 35688322 | J Pharmacol Toxicol Methods | Establishment of a new nonalcoholic steatohepatitis model; Ovariectomy exacerbates nonalcoholic steatohepatitis-like pathology in diabetic rats. | 2022 | Details |
| A49652 | 35678800 | Turk J Gastroenterol | Effects of Orlistat or Telmisartan on the Serum Free Fatty Acids in Non-alcoholic Fatty Liver Disease Patients: An Open-Labeled Randomized Controlled Study. | 2022 | Details |
| A49659 | 35677507 | J Clin Exp Hepatol | Nonalcoholic Steatohepatitis: A Rapidly Increasing Indication for Liver Transplantation in India. | 2021 | Details |
| A49663 | 35677499 | J Clin Exp Hepatol | Prevalence of Non-alcoholic Fatty Liver Disease in India: A Systematic Review and Meta-analysis. | 2021 | Details |
| A49677 | 35673435 | J Diabetes Metab Disord | The triglyceride-glucose index as a clinical useful marker for metabolic associated fatty liver disease (MAFLD): a population-based study among Iranian adults. | 2022 | Details |
| A49683 | 35672152 | Pharm Biol | Camel milk protein hydrosylate alleviates hepatic steatosis and hypertension in high fructose-fed rats. | 2022 | Details |
| A49685 | 35671811 | Life Sci | Vildagliptin alleviates liver fibrosis in NASH diabetic rats via modulation of insulin resistance, oxidative stress, and inflammatory cascades. | 2022 | Details |
| A49704 | 35663787 | Int J Pediatr Adolesc Med | Treatment of hyperglycemia not associated with NAFLD improvement in children with type 2 diabetes mellitus. | 2021 | Details |
| A49705 | 35663319 | Front Endocrinol (Lausanne) | High Prevalence of Cardiometabolic Comorbidities Among Children and Adolescents With Severe Obesity From a Large Metropolitan Centre (Hangzhou, China). | 2022 | Details |
| A49709 | 35662921 | Front Nutr | High Protein Diets Improve Liver Fat and Insulin Sensitivity by Prandial but Not Fasting Glucagon Secretion in Type 2 Diabetes. | 2022 | Details |
| A49714 | 35661191 | Aliment Pharmacol Ther | Review article: vascular effects of PPARs in the context of NASH. | 2022 | Details |
| A49718 | 35659603 | Clin Res Hepatol Gastroenterol | Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2022 | Details |
| A49724 | 35657189 | Rev Med Liege | [Non-alcoholic steatohepatitis (NASH) : a model of metabolic inflammation («metaflammation»)]. | 2022 | Details |
| A49725 | 35657127 | Arch Endocrinol Metab | Risk factors associated with nonalcoholic fatty liver disease evaluated by elastography in patients with type 2 diabetes. | 2022 | Details |
| A49739 | 35654114 | Metabolism | GW9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease. | 2022 | Details |
| A49742 | 35651978 | Front Endocrinol (Lausanne) | Non-alcoholic Fatty Liver Disease Is Associated With Aortic Calcification: A Cohort Study With Propensity Score Matching. | 2022 | Details |
| A49743 | 35651973 | Front Endocrinol (Lausanne) | Contribution of Liver and Pancreatic Islet Crosstalk to β-Cell Function/Dysfunction in the Presence of Fatty Liver. | 2022 | Details |
| A49748 | 35650449 | Pharm Res | Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review. | 2022 | Details |
| A49760 | 35645140 | Saudi J Gastroenterol | Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study. | 2022 | Details |
| A49761 | 35644970 | Zhonghua Yu Fang Yi Xue Za Zhi | [The characteristics of non-alcoholic fatty liver disease and its associated factors in patients with rheumatoid arthritis]. | 2022 | Details |
| A49767 | 35643859 | Lab Invest | A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis. | 2022 | Details |
| A49776 | 35641932 | BMC Endocr Disord | Correlation between the thyroid hormone levels and nonalcoholic fatty liver disease in type 2 diabetic patients with normal thyroid function. | 2022 | Details |
| A49779 | 35639744 | PLoS One | A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis. | 2022 | Details |
| A49783 | 35639037 | J Physiol Pharmacol | Are insulin resistance and non-alcoholic fatty liver disease associated with Peyronie's disease? A pilot study. | 2022 | Details |
| A49792 | 35636169 | Phytomedicine | Pharmacological effects of polydatin in the treatment of metabolic diseases: A review. | 2022 | Details |
| A49805 | 35631319 | Nutrients | Reduction of De Novo Lipogenesis Mediates Beneficial Effects of Isoenergetic Diets on Fatty Liver: Mechanistic Insights from the MEDEA Randomized Clinical Trial. | 2022 | Details |
| A49808 | 35630668 | Molecules | Non-Alcoholic Fatty Liver Disease in Long-Term Type 2 Diabetes: Role of rs738409 PNPLA3 and rs499765 FGF21 Polymorphisms and Serum Biomarkers. | 2022 | Details |
| A49820 | 35628485 | Int J Mol Sci | Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice. | 2022 | Details |
| A49821 | 35628443 | Int J Mol Sci | Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models. | 2022 | Details |
| A49838 | 35624769 | Antioxidants (Basel) | Ramulus Mori (Sangzhi) Alkaloids Alleviate High-Fat Diet-Induced Obesity and Nonalcoholic Fatty Liver Disease in Mice. | 2022 | Details |
| A49863 | 35615095 | Front Med (Lausanne) | Endoscopic Bariatric and Metabolic Therapies and Their Effects on Metabolic Syndrome and Non-alcoholic Fatty Liver Disease - A Systematic Review and Meta-Analysis. | 2022 | Details |
| A49865 | 35614896 | Visc Med | Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review. | 2021 | Details |
| A49867 | 35614469 | Cardiovasc Diabetol | The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. | 2022 | Details |
| A49873 | 35612975 | Nephrol Dial Transplant | Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than does fatty liver or nonalcoholic fatty liver disease. | 2022 | Details |
| A49915 | 35598211 | Orv Hetil | A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség. | 2022 | Details |
| A49921 | 35595482 | Prim Care | Diabetes-Associated Comorbidities. | 2022 | Details |
| A49943 | 35586202 | Diabetes Metab Syndr Obes | The Perirenal Fat Thickness Was Associated with Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. | 2022 | Details |
| A49954 | 35583582 | Chin J Integr Med | Molecular Mechanism of Polysaccharides Extracted from Chinese Medicine Targeting Gut Microbiota for Promoting Health. | 2022 | Details |
| A49961 | 35582126 | World J Gastroenterol | Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease. | 2022 | Details |
| A49962 | 35581956 | Hepatol Commun | Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study. | 2022 | Details |
| A49970 | 35578445 | Hepatol Commun | Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial. | 2022 | Details |
| A49971 | 35578028 | Inflamm Res | Prolonged effects of DPP-4 inhibitors on steato-hepatitic changes in Sprague-Dawley rats fed a high-cholesterol diet. | 2022 | Details |
| A49977 | 35575004 | Hepatol Res | High fatty liver index is an independent predictor of ischemic heart disease during a 10-year period in a Japanese population. | 2022 | Details |
| A49988 | 35569886 | Endocr Pract | American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). | 2022 | Details |
| A49993 | 35568374 | Biochim Biophys Acta Mol Cell Biol Lipids | Implications of microbe-mediated crosstalk in the gut: Impact on metabolic diseases. | 2022 | Details |
| A50017 | 35563117 | Int J Mol Sci | Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate. | 2022 | Details |
| A50019 | 35562689 | BMC Endocr Disord | Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged ≥ 40 years. | 2022 | Details |